The Centers for Disease Control and Prevention (CDC) reported 3,434 kratom-related poisonings in 2024, a 1,200% increase since 2015. The data reflects growing concerns about the substance’s potential for addiction and health risks, as cases involving synthetic kratom derivatives—particularly 7-OH—continue to rise.
Two individuals’ experiences highlight opposing perspectives on kratom’s dangers and perceived benefits. A 30-year-old Michigan woman, Hilary Tesluck, described her descent into addiction after initially using kratom capsules in 2017 for anxiety relief. Tesluck’s daily intake escalated from four capsules to 100 per day, leading to severe weight loss, job performance issues, and physical deterioration. She now advocates for awareness of kratom’s addictive potential. In contrast, Melanie Clark, a Michigan mother struggling with postpartum depression, reported using a kratom-based energy drink, Feel Free Classic Tonic, to boost her energy and focus. Clark described initial positive effects but later recognized signs of dependence.
Kratom’s legal status and industry claims further complicate the debate. The substance, derived from a Southeast Asian tree, is legally sold in most U.S. states and marketed by the American Kratom Association (AKA) as a natural supplement for energy and opioid withdrawal support. The AKA distinguishes between natural leaf kratom and concentrated 7-OH products, acknowledging dependence risks associated with the latter. However, health experts and families of deceased users argue that kratom’s opioid-like effects pose serious health threats. Dr. Andrew Kolodny, medical director of the Opioid Policy Research Collaborative at Brandeis University, likened kratom’s effects to those of oxycodone and fentanyl. The CDC has detected kratom in more than 5,000 overdose deaths from 2020 to 2024, though in many cases, other substances were also present.
Regulatory and industry responses reflect the divide. The kratom industry emphasizes its potential as a harm-reduction tool, citing anecdotal success stories in opioid recovery. Meanwhile, critics point to rising poison control reports and fatalities as evidence of unchecked risks. The CDC’s data, combined with personal accounts of addiction and death, underscores the need for further research and potential regulatory scrutiny.
What is kratom?
Kratom (Mitragyna speciosa) is a tropical tree native to Southeast Asia, where its leaves have been chewed or brewed into tea for centuries. In the U.S., it is sold as capsules, powders, teas, and energy drinks, often marketed for pain relief, energy, or opioid withdrawal. The substance contains mitragynine and 7-hydroxymitragynine (7-OH), compounds that interact with opioid receptors. While some users report benefits, others describe severe dependence, withdrawal symptoms, and life-threatening health effects.
Health risks and addiction patterns
Reports to U.S. poison centers have surged alongside kratom’s commercial availability. Users like Tesluck and Clark illustrate two distinct pathways: one of escalating dependence and another of perceived therapeutic use. Tesluck’s case reflects a gradual increase in tolerance, leading to extreme consumption and physical decline. Clark’s experience, while initially positive, highlights how kratom’s accessibility—available in gas stations and corner markets—can facilitate unintended overuse. Health professionals warn that kratom’s opioid-like properties can lead to respiratory depression, seizures, and fatal overdoses, particularly when combined with other substances.
Industry and advocacy perspectives
The American Kratom Association (AKA) argues that natural leaf kratom is a safe, non-addictive supplement when used responsibly. The group advocates for consumer education and opposes bans, citing its role in harm reduction for opioid users. However, critics, including Dr. Kolodny and families of deceased users, contend that kratom’s risks outweigh its benefits. They point to the CDC’s overdose data and personal tragedies as evidence that the substance’s legal status enables widespread harm.
Policy and regulatory landscape
Kratom remains legal in most U.S. states, though some municipalities have imposed restrictions. The FDA has not approved kratom for medical use, and the agency has issued warnings about its safety. The CDC’s poison control data has intensified calls for federal oversight, with some lawmakers and health experts urging the Drug Enforcement Administration (DEA) to classify kratom as a controlled substance. Meanwhile, the kratom industry continues to lobby against restrictions, emphasizing its economic impact and the rights of users who report benefits.
Personal accounts and broader implications
The stories of Tesluck and Clark reflect the broader societal divide over kratom. Tesluck’s recovery journey and advocacy work highlight the human cost of unchecked use, while Clark’s experience raises questions about the substance’s accessibility and marketing. Both cases underscore the need for clearer labeling, public education, and further research to determine kratom’s long-term effects. As the debate continues, families, health professionals, and policymakers remain at odds over whether kratom is a dangerous opioid or a misunderstood herbal remedy.